Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Mylan lowers outlook after Q2 earnings, sales miss estimates

August 8, 2018 By Sarah Faulkner

MylanShares in Mylan (NSDQ:MYL) fell today after the pharmaceutical company missed expectations on Wall Street with its second-quarter financial results.

The Canonsburg, Penn.-based company posted profits of $37.5 million, or 7¢ per share, on sales of $2.8 billion for the three months ended June 30, representing a bottom-line loss of -87.4% on a sales loss of 5% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were $1.07, behind consensus on The Street, where analysts were looking for sales of $2.96 billion.

“During the second quarter, Mylan continued to do its part to expand access to medicine around the world. Our Europe and Rest of World segments continue to deliver growth in line with our expectations. However, our efforts to serve patients in the U.S. have been shaped by the industry’s transformation there, and our results and guidance for 2018 are directly correlated with the ongoing rebasing of the U.S. healthcare environment,” CEO Heather Bresch said in prepared remarks.

“That said, the fundamentals of Mylan’s global business remain strong. We’re especially confident in our ability to deliver on Mylan’s long-stated global strategy, which is predicated on driving access to medicine through scale, a diversified portfolio and geographic reach. The result is a durable global business capable of delivering on our mission for years to come,” Bresch added.

Mylan said it expects to post sales of $11.25 billion to $12.25 billion for the full year, down from its previous range of $11.75 billion to $13.25 billion.

The company also announced that its board of directors has formed a strategic review committee to evaluate “a wide range of alternatives to unlock the true value of our one-of-a-kind platform.”

“We believe that the US public markets continue to underappreciate and undervalue the durability, differentiation and strengths of Mylan’s global diversified business, especially when compared to our peers around the globe,” Mylan’s board said in a statement. “The Board has not set a timetable for its evaluation of alternatives and there can be no assurance that any alternative will be implemented.”

MYL shares were trading at $36.09 apiece today in morning activity, down -6%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Mylan

IN CASE YOU MISSED IT

  • Leo Pharma, Portal Instruments partner to develop needle-free drug delivery device
  • J&J’s Ethicon launches Vistaseal fibrin sealant
  • Senseonics launches Eversense CGM System with non-adjunctive claim
  • ‘Hubble Space Telescope’ for genomics could yield new drugs, materials
  • OncoSec $30m fundraise threatened by spat
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS